Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 16 December 2025 - 21 December 2025

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight heading into December 20, 2025—not because of a single blockbuster headline, but because the stock just posted a sharp, high-volume move that traders and long-term biotech investors both tend to notice. With Edgewise still a clinical-stage company, the share price often reflects a shifting mix of (1) expectations for clinical…
21 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh…
20 December 2025
·····
Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Stock (TMO) News Today: What’s Driving Shares, Analyst Forecasts, and Key Catalysts on Dec. 19, 2025

Thermo Fisher Scientific Inc. (NYSE: TMO) is back in the spotlight on Friday, December 19, 2025, as investors weigh a fresh set of operational updates, capital-return signals, and Wall Street forecasts. Shares were trading around $569.54, up about 1.27% on the day, giving the life sciences and diagnostics giant a market value near $218 billion. While Thermo Fisher is often…
19 December 2025
·····
Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

Edgewise Therapeutics (EWTX) Stock News and Forecast: Why Shares Rebounded on Dec. 19, 2025—and What Analysts Are Watching Next

December 19, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is back in the spotlight after a sharp one-day rebound that followed a volatile stretch for the clinical-stage biotech. EWTX closed Dec. 19, 2025 at $23.01, up +8.79% on the day after trading between roughly $21.49 and $23.84 on elevated activity. Investing For investors, today’s price action is the “symptom.” The…
19 December 2025
····
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio

BioMarin Pharmaceutical is set to deepen its push into rare metabolic diseases after announcing a definitive agreement to acquire Amicus Therapeutics in an all‑cash transaction valued at approximately $4.8 billion. The deal would add two marketed therapies—Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease—while also bringing in a Phase 3 kidney-disease program that could widen BioMarin’s late‑stage…
19 December 2025
····
Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

Thermo Fisher Scientific (TMO) Stock Today: Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)

WALTHAM, Mass. / Markets — December 18, 2025: Thermo Fisher Scientific Inc. (NYSE: TMO) is in focus Thursday as investors weigh a new Alzheimer’s real‑world evidence initiative from its PPD CorEvitas clinical registries business alongside a steady stream of Wall Street forecasts and valuation takes. Shares were trading around $561 in the afternoon, modestly lower on the day, after a…
18 December 2025
····
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because…
18 December 2025
·····
Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts

December 18, 2025 — Insmed Incorporated (NASDAQ: INSM) shares dropped sharply Thursday after the company disclosed a Phase 2b setback for brensocatib in a chronic sinus condition and said it is discontinuing development in that indication, even as it simultaneously added a new Phase 2–ready antibody to its pipeline. SEC Insmed stock was trading around $166.75 in the afternoon snapshot…
18 December 2025
·····
Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals (TLX) Stock Slides on Dec. 17, 2025: ProstACT Phase 3 Update, FDA Zircaix Overhang, Lawsuit Headlines, and Fresh Analyst Forecasts

Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) entered the spotlight again on December 17, 2025, as TLX stock extended its December sell-off amid a fast-moving mix of clinical-trial updates, regulatory overhang, and investor litigation headlines. Telix Pharmaceuticals On the ASX, Telix shares closed at A$11.73, down 6.61% on the session, with a wide intraday range from A$11.535 to A$12.730 and volume of…
17 December 2025
······
Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience (TWST) Stock News Today: Latest Catalysts, Analyst Forecasts, and 2026 Outlook (Dec. 17, 2025)

Twist Bioscience Corporation (NASDAQ: TWST) is drawing fresh attention on Wednesday, December 17, 2025, as the stock trades sharply higher amid a mix of new partnership-related headlines, recent product launches, and updated Wall Street price targets. At the same time, investors are weighing Twist’s push toward higher gross margins and management’s goal to reach adjusted EBITDA breakeven by fiscal Q4…
17 December 2025
·····
Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt (ADTX) Stock Surges After Proxy Filing Sets Up Reverse Split Vote and “bitXbio” Name Change — What to Know on Dec. 17, 2025

Aditxt, Inc. (NASDAQ: ADTX) is back in the spotlight on December 17, 2025, after a sharp move tied to a newly filed shareholder proxy—one that tees up high-stakes votes on potential dilution, a possible reverse stock split, and a proposed rebrand to “bitXbio, Inc.” Benzinga This is the kind of micro-cap biotech story that can turn on a single filing:…
17 December 2025
····
Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics (GPCR) Stock: Why Shares Are Sliding on Dec. 16, 2025 After Breakout Obesity Pill Data and a $747.5M Offering

Structure Therapeutics Inc. (NASDAQ: GPCR) is having a classic biotech moment on Tuesday, December 16, 2025: big catalyst, big financing, and now big volatility. Shares were down about 6% in Tuesday trading, recently around $60.73, after swinging between roughly $58.95 and $65.69 intraday. The pullback comes just days after the company reported positive topline Phase 2b results for its oral…
16 December 2025
····
1 … 9 10 11 12 13 … 25

Stock Market Today

  • Exxon Mobil Q4 Beat Highlights Permian and Guyana Output, Valuation at Crossroads
    February 2, 2026, 1:48 PM EST. Exxon Mobil (XOM) posted better-than-expected Q4 2025 results, driven by record upstream production in the Permian Basin and Guyana, alongside notable cost savings. The stock gained 15.29% over the past month and delivered a 36.88% total return over the past year. Despite trading above the average analyst target price of $134.04 at $141.40, a valuation model from Helzur suggests the stock is 7.1% overvalued, with a fair value estimated at $132.00 per share. This assessment emphasizes Exxon's strong cash flow, disciplined capital allocation, and operational excellence without relying on high oil price assumptions. Risks remain from commodity price volatility and potential policy-driven decarbonization impacts on upstream and Low Carbon Solutions business units.
Go toTop